Helex Biotech Aims to Revolutionize Kidney Gene Therapy in India
Hyderabad-based startup develops targeted lipid nanoparticle technology for affordable, single-dose genetic kidney treatments.
1Targeting Kidney Cell Therapy
Helex Inc is developing a first-in-class genetic medicine platform designed to deliver drugs specifically into kidney cells. The startup aims to overcome significant medical challenges regarding toxicity and precise dosing. By focusing on autosomal dominant polycystic kidney disease, the firm seeks to provide a transformative, single-shot treatment for patients.
2Founding Vision and Expertise
Founded by Anirudh Nishtala, Poulami Chaudhuri, and Rohini Kalvakuntla, the company leverages diverse backgrounds in molecular science, global healthcare consulting, and pharmaceutical operations. The trio established the startup in Hyderabad to bridge the gap between advanced global innovation and the urgent need for affordable, high-quality medical solutions within India.
3Proprietary Drug Delivery Mechanism
The core technology utilizes in-house developed lipid nanoparticles to encapsulate and transport gene-editing agents directly to target cells. This system is engineered to safely navigate the body and edit faulty genomes, potentially reversing disease progression. This approach contrasts with current small-molecule therapies that often require repeat dosing and carry risks.
4Preclinical Validation Milestones
While the lead candidate has not yet entered human clinical trials, Helex has successfully demonstrated that its lipid nanoparticles can enter and edit target cells in mice and non-human primates. The team is currently preparing an investigational new drug application to advance toward phase 1 safety trials in humans.
5Regulatory and Facility Standards
Helex recently relocated to a larger laboratory in Hyderabad’s Genome Valley to support its research and development requirements. The facility is designed to comply with Schedule M regulatory standards, which mandate good manufacturing practices under Indian law. This infrastructure ensures the company maintains quality levels aligned with rigorous global pharmaceutical benchmarks.
6Capital Strategy and Funding
The startup has raised $6.2 million across pre-seed and seed rounds, with support from investors like pi Ventures, Bluehill Capital, and SOSV. Helex is currently preparing for a Series A round to finance upcoming clinical trials. They maintain capital efficiency by operating as a hybrid entity between India and the US.
7Economic Model for Affordability
To ensure treatments remain accessible, Helex plans to retain commercial rights within India, allowing full control over local pricing strategies. Simultaneously, the firm intends to pursue licensing deals with larger global pharmaceutical companies for developed markets. This dual-track strategy aims to balance revenue generation with the company's core mission of affordability.
8Strategic Industry Positioning
Helex represents a growing wave of Indian biotech firms attempting to innovate within a sparse ecosystem. By focusing on genetic drivers rather than just symptom management, the company positions itself to disrupt the market for chronic kidney conditions. Their success depends on proving safety in early-stage trials and securing future partnerships.